Stock Financial Ratios

HRTX / Heron Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,197.29
Enterprise Value ($M)838.45
Book Value ($M)-21.25
Book Value / Share-0.56
Price / Book30.97
NCAV ($M)-1.76
NCAV / Share-0.05
Price / NCAV21.87
Income Statement (mra) ($M)
Net Income-173.14
Balance Sheet (mrq) ($M)
Cash & Equivalents65.52
Cash / Share1.73
Quick Ratio0.67
Current Ratio0.81
Management Effectiveness (mra)
Return on Invested Capital (ROIC)8.15
Return on Assets (ROA)-4.83
Return on Equity (ROE)8.15
Identifiers and Descriptors
Central Index Key (CIK)818033
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
Share Statistics
Common Shares Outstanding (M)54.50
Scoring Models
Piotroski F Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Deferred Income Tax Liabilities Per Share0.00
Liabilities Per Share2.06
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Inventory Raw Materials Per Share0.00
Property Plant And Equipment Net Per Share0.14
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Cash Per Share1.73
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Accounts Receivable Per Share0.76
Accumulated Depreciation And Depletion Per Share0.00
Minority Interest Per Share0.00
Assets Other Non Current Per Share0.01
Inventory Work In Progress Per Share0.00
Liabilities And Stock Equity Per Share3.12
Assets Per Share3.72
Long Term Debt Per Share0.00
Additional Paid In Capital Per Share20.05
Treasury Stock Per Share0.00
Equity Per Share1.06
Debt Per Share0.00
Liabilities Current Per Share1.25
Property Plant And Equipment Per Share0.14
Cash And Equivalents Per Share1.73
Intangibles Per Share0.00
Goodwill Per Share0.00
Inventory Per Share0.14
Retained Earnings Per Share-19.01
Assets Current Per Share3.58

Related News Stories

Biotech Daily Digest For January 16th

2018-01-16 seekingalpha
Biotech is rising in 2018 but still lags other sectors that will see more direct impacts from the recently passed tax legislation. (685-1)

Heron: Strong Position With Product Launch Upcoming

2018-01-03 seekingalpha
Heron Therapeutics Inc. (NASDAQ:HRTX) recently announced the FDA approval for its drug candidate for chemotherapy induced nausea and vomiting condition, or CINV. This development is an important milestone for the company which currently has only one marketed drug in its portfolio. The company has shown steady improvement in its financial performance as well and the trend is likely to continue into the coming quarters as well, making this stock an interesting investment opportunity. (18-1)

Your Daily Pharma Scoop: Heron Enters 2018 On Strong Note, Teva Launches Generic Reyataz, Sarepta Top Smid-Cap Pick

2017-12-29 seekingalpha
Heron has seen strong gains this year and is poised for another solid year in 2018. (80-0)

Biotech Forum Daily Digest: Impacts Of Tax Reform

2017-12-15 seekingalpha
Biotech has been a volatile sector in trading this week. Tax loss selling and uncertainty of what will be in the final tax reform package are both probably impacting trading. (103-1)

10 Strong Buy Stocks That Are Better Than Bitcoin | InvestorPlace

2017-12-14 investorplace
No one can deny the huge hype bitcoin is generating right now … and for lucky investors, it has also proved a very profitable investment. But with such huge gains come huge risks — and even greater volatility. (274-4)

CUSIP: 427746102